G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer - Concepedia

Concepedia

Publication | Open Access

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

DOI Full Paper Access

46

Citations

54

References

2020

Year

Kaitlyn J. Andreano, Suzanne E. Wardell, Jennifer G. Baker, Taylor K. Desautels, Robert Baldi, Christina Chao, Kendall A. Heetderks, Yeeun Bae, Rui Xiong, Debra A. Tonetti,

Breast Cancer Research and Treatment

Abstract

These data show that G1T48 has the potential to be an efficacious oral antineoplastic agent in ER-positive breast cancer.

References

	Year	Citations

Page 1